AVITA Medical Appoints New Board Director
AVITA Medical, Inc. (NASDAQ: RCEL), a leader in the acute wound care sector, has announced the addition of Dr. Michael Tarnoff, MD, FACS, as a non-executive director. This significant announcement marks a critical step in the Company’s growth and dedication to advancing innovative wound-healing technologies.
Strengthening Leadership with Expertise
Dr. Tarnoff brings a wealth of experience, having held executive positions at Tufts Medical Center and Medtronic, among other organizations. His appointment comes as the Company prioritizes patient-centric care, enhancing its impact within hospitals, burn centers, and trauma care settings. CEO Jim Corbett expressed enthusiasm about Dr. Tarnoff’s integration into the Board, highlighting his innovation-driven approach as essential for scaling AVITA's initiatives.
Guided by a Mission
Commenting on his new role, Dr. Tarnoff stated, "AVITA's commitment to transforming wound care resonates deeply with me. I look forward to guiding the organization as it continues to innovate and improve patient outcomes." His extensive background in clinical innovation positions him as a vital asset to the Company’s strategic vision.
Transition in Board Leadership
In a related development, AVITA Medical has also announced changes in its Board leadership. Cary Vance has been elected as the new Board Chair, succeeding Lou Panaccio, who is stepping down after ten years of distinguished service. Vance’s passion for innovation and his proven leadership in the healthcare industry are expected to significantly contribute to the Company’s future direction.
About AVITA Medical, Inc.
AVITA Medical is renowned for its pioneering technologies aimed at optimizing wound healing and expediting patient recovery. Central to its offerings is the RECELL® System, which utilizes a patient's own skin to create Spray-On Skin™ Cells to treat thermal burn wounds and trauma injuries effectively. This innovative approach ensures improved clinical outcomes across various care settings.
The RECELL System is also recognized internationally, receiving approvals in markets such as Australia and Europe to aid in the healing of skin defects and burns. In the U.S., AVITA holds exclusive rights to manufacture and market PermeaDerm®, as well as Cohealyx™, enhancing its extensive wound care portfolio.
AVITA Medical remains committed to its mission of redefining wound care and being at the forefront of medical advancements. The infusion of new leadership with Dr. Tarnoff and Mr. Vance strengthens the Company's resolve to innovate and expand its impact on patient care.
Frequently Asked Questions
Who has been appointed to AVITA Medical's Board of Directors?
Dr. Michael Tarnoff has been appointed as a non-executive director.
What leadership change has occurred at AVITA Medical?
Cary Vance has been elected as the new Board Chair, succeeding Lou Panaccio.
What is the main focus of AVITA Medical?
AVITA Medical focuses on delivering innovative solutions for acute wound care.
Where is the RECELL® System approved for use?
The RECELL® System is approved in the U.S., Australia, Europe, and Japan for various skin healing applications.
What technologies does AVITA Medical offer?
AVITA Medical offers the RECELL® System and holds exclusive rights to PermeaDerm® and Cohealyx™ for wound care.
